X0407 4 2021-10-08 true 0001092662 CHEMBIO DIAGNOSTICS, INC. CEMI 0001397402 Esfandiari Javan C/O CHEMBIO DIAGNOSTICS, INC. 3661 HORSEBLOCK ROAD MEDFORD NY 11763 true See Remarks false Common Stock 2021-10-08 4 F 0 4940 2.38 D 93408 D Common Stock 2022-03-15 4 M 0 12903 A 106311 D Common Stock 2023-03-11 4 M 0 48000 A 154311 D Common Stock 2023-03-11 4 F 0 16950 0.44 D 137361 D Common Stock 2023-03-15 4 M 0 12903 A 150264 D Common Stock 2023-03-15 4 F 0 4652 0.39 D 145612 D Common Stock 2023-04-26 4 U 0 145612 0.45 D 0 D Restricted stock units 2022-03-15 4 M 0 12903 0 D Common stock 12903 25807 D Restricted stock units 2023-03-11 4 M 0 48000 0 D Common stock 48000 96000 D Restricted stock units 2023-03-15 4 M 0 12903 0 D Common stock 12903 12904 D Restricted stock units 2023-04-27 4 D 0 108904 D Common stock 108904 0 D Incentive stock options 2.36 2023-04-27 4 D 0 188064 D 2027-03-15 Common stock 188064 0 D Incentive stock options 4.65 2023-04-27 4 D 0 107143 D 2028-03-14 Common stock 107143 0 D Incentive stock options 1.25 2023-04-27 4 D 0 277714 D 2032-03-10 Common stock 69435 0 D Nonqualified stock options 1.25 2023-04-27 4 D 0 277714 D 2032-03-10 Common stock 208279 0 D These shares were withheld for tax purposes upon the vesting of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock. Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated January 31, 2023 (the "Merger Agreement"), by and among the Issuer, Biosynex SA ("Parent"), and Project Merci Merger Sub, Inc. ("Purchaser"), including the completion on April 26, 2023 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $0.45 per share in cash, without interest (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Purchaser on April 27, 2023. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price. On March 15, 2021, the reporting person was granted 38,710 restricted stock units which vested over three years, with one-third vesting on March 15, 2022, one-third vesting on March 15, 2023, and the remaining one-third vesting on March 15, 2024, subject to continued service through each vesting date. On March 11, 2022, the reporting person was granted 144,000 restricted stock units scheduled to vest in equal installments on March 11 of each of 2023, 2024 and 2025, subject to continued service through each vesting date. Each Company RSU (as defined in the Merger Agreement) that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (a) the total number of Shares (as defined the Merger Agreement) issuable in settlement of such Company RSU immediately prior to the Effective Time without regard to vesting multiplied by (b) the Merger Consideration (as defined in the Merger Agreement). As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an "Out of the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Executive Vice President, Chief Science and Technology Officer /s/ Javan Esfandiari 2023-05-01